CL2020000627A1 - Nueva combinación de agentes activos para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas (pf-ild). - Google Patents
Nueva combinación de agentes activos para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas (pf-ild).Info
- Publication number
- CL2020000627A1 CL2020000627A1 CL2020000627A CL2020000627A CL2020000627A1 CL 2020000627 A1 CL2020000627 A1 CL 2020000627A1 CL 2020000627 A CL2020000627 A CL 2020000627A CL 2020000627 A CL2020000627 A CL 2020000627A CL 2020000627 A1 CL2020000627 A1 CL 2020000627A1
- Authority
- CL
- Chile
- Prior art keywords
- ild
- treatment
- active agents
- therapeutically effective
- interstitial lung
- Prior art date
Links
- 208000029523 Interstitial Lung disease Diseases 0.000 title 1
- 239000013543 active substance Substances 0.000 title 1
- 230000000750 progressive effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 abstract 2
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 101100138673 Arabidopsis thaliana NPF3.1 gene Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 abstract 1
- 229960004378 nintedanib Drugs 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA SOLICITUD SE REFIERE A UN TRATAMIENTO CONJUNTO O COMBINACIÓN DE MEDICAMENTOS NOVEDOSO PARA EL TRATAMIENTO DE PF-ILD, QUE COMPRENDE, COMO PRIMER COMPONENTE DE COMBINACIÓN, UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE NINTEDANIB O UNA SAL DE ESTE ACEPTABLE DESDE EL PUNTO DE VISTA FARMACÉUTICO Y, COMO SEGUNDO COMPONENTE DE COMBINACIÓN, UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE UN INHIBIDOR DE PDE4B DE LA FÓRMULA I, EN DONDE EL ANILLO A ES UN ANILLO AROMÁTICO DE 6 MIEMBROS QUE OPCIONALMENTE PUEDE COMPRENDER UNO O DOS ÁTOMOS DE NITRÓGENO Y EN DONDE R ES CL, Y EN DONDE R PUEDE ESTAR UBICADO EN LA POSICIÓN PARA, META U ORTO DEL ANILLO A, EN DONDE S* ES UN ÁTOMO DE AZUFRE QUE REPRESENTA UN CENTRO QUIRAL O UNA SAL DE AQUEL ACEPTABLE DESDE EL PUNTO DE VISTA FARMACÉUTICO. SEGÚN LA PRESENTE, EL SEGUNDO COMPONENTE DE COMBINACIÓN ES, PREFERENTEMENTE, UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DEL INHIBIDOR DE PDE4B DE LA FÓRMULA III, O UNA SAL DE AQUEL ACEPTABLE DESDE EL PUNTO DE VISTA FARMACÉUTICO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17197719 | 2017-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000627A1 true CL2020000627A1 (es) | 2020-08-21 |
Family
ID=60162029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000627A CL2020000627A1 (es) | 2017-10-23 | 2020-03-11 | Nueva combinación de agentes activos para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas (pf-ild). |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11406638B2 (es) |
| EP (1) | EP3700529A1 (es) |
| JP (1) | JP7196169B2 (es) |
| KR (1) | KR20200075864A (es) |
| CN (1) | CN111278442B (es) |
| AU (2) | AU2018357775B2 (es) |
| BR (1) | BR112020003973A2 (es) |
| CA (1) | CA3079299A1 (es) |
| CL (1) | CL2020000627A1 (es) |
| EA (1) | EA202090977A1 (es) |
| IL (2) | IL309150A (es) |
| MA (1) | MA50441A (es) |
| MX (1) | MX2020004173A (es) |
| PH (1) | PH12020550452A1 (es) |
| TW (1) | TWI700088B (es) |
| WO (1) | WO2019081235A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113116904B (zh) * | 2021-03-23 | 2022-11-29 | 深圳市泰力生物医药有限公司 | 尼达尼布-甘草次酸复方制剂和药物复方制剂及在制备治疗肺纤维化药物中的应用 |
| TW202339731A (zh) | 2021-12-09 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法 |
| US20230190754A1 (en) | 2021-12-09 | 2023-06-22 | Boehringer Ingelheim International Gmbh | Therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases |
| WO2023235267A2 (en) * | 2022-05-28 | 2023-12-07 | Avalyn Pharma Inc. | Nintedanib and nintedanib combination dry powder compositions and uses |
| WO2023232135A1 (zh) * | 2022-06-02 | 2023-12-07 | 西藏海思科制药有限公司 | Pde4b抑制剂及其用途 |
| CN117247394A (zh) * | 2022-06-16 | 2023-12-19 | 武汉人福创新药物研发中心有限公司 | 作为pde4b抑制剂的含氮杂环类化合物 |
| WO2024032673A1 (zh) * | 2022-08-09 | 2024-02-15 | 西藏海思科制药有限公司 | Pde4b抑制剂及其用途 |
| WO2024068386A1 (en) | 2022-09-28 | 2024-04-04 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1049411A (en) | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
| CA2165192C (en) | 1993-07-02 | 2001-04-24 | Hermann Amschler | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6762180B1 (en) | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| DE102004057595A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057594A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057645A1 (de) | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057618A1 (de) | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| PE20060777A1 (es) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| DE102005019201A1 (de) | 2006-04-19 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen |
| EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
| EP1870400A1 (en) | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
| CA2705414C (en) | 2007-10-19 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Substituted piperidino-dihydrothienopyrimidines |
| CN101827853A (zh) | 2007-10-19 | 2010-09-08 | 贝林格尔.英格海姆国际有限公司 | 杂环取代的哌嗪子基-二氢噻吩并嘧啶 |
| EA029996B1 (ru) | 2008-06-06 | 2018-06-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Капсулярная лекарственная форма, содержащая суспензионную композицию производного индолинона |
| UA107560C2 (uk) | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| US9802954B2 (en) * | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| WO2014124860A1 (en) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Specific pde4b-inhibitors for the treatment of diabetes mellitus |
| CN106535896B (zh) * | 2015-04-27 | 2019-06-21 | 江苏恒瑞医药股份有限公司 | 蛋白激酶抑制剂在制备治疗纤维化疾病的药物中的用途 |
| CZ308695B6 (cs) * | 2015-07-29 | 2021-03-03 | Zentiva, K.S. | Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu) |
-
2018
- 2018-10-12 EA EA202090977A patent/EA202090977A1/ru unknown
- 2018-10-12 MX MX2020004173A patent/MX2020004173A/es unknown
- 2018-10-12 IL IL309150A patent/IL309150A/en unknown
- 2018-10-12 EP EP18785961.6A patent/EP3700529A1/en active Pending
- 2018-10-12 BR BR112020003973-0A patent/BR112020003973A2/pt unknown
- 2018-10-12 MA MA050441A patent/MA50441A/fr unknown
- 2018-10-12 WO PCT/EP2018/077952 patent/WO2019081235A1/en unknown
- 2018-10-12 AU AU2018357775A patent/AU2018357775B2/en active Active
- 2018-10-12 IL IL273169A patent/IL273169B2/en unknown
- 2018-10-12 CA CA3079299A patent/CA3079299A1/en active Pending
- 2018-10-12 CN CN201880068509.6A patent/CN111278442B/zh active Active
- 2018-10-12 JP JP2020522715A patent/JP7196169B2/ja active Active
- 2018-10-12 KR KR1020207014628A patent/KR20200075864A/ko not_active Application Discontinuation
- 2018-10-22 US US16/166,239 patent/US11406638B2/en active Active
- 2018-10-22 TW TW107137119A patent/TWI700088B/zh active
-
2020
- 2020-03-11 CL CL2020000627A patent/CL2020000627A1/es unknown
- 2020-04-20 PH PH12020550452A patent/PH12020550452A1/en unknown
-
2022
- 2022-07-12 US US17/811,914 patent/US11813266B2/en active Active
-
2023
- 2023-06-29 US US18/343,792 patent/US20230405010A1/en active Pending
-
2024
- 2024-05-08 AU AU2024203045A patent/AU2024203045A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL273169A (en) | 2020-04-30 |
| CN111278442B (zh) | 2023-06-06 |
| MX2020004173A (es) | 2020-08-03 |
| AU2018357775B2 (en) | 2024-02-15 |
| US11406638B2 (en) | 2022-08-09 |
| EA202090977A1 (ru) | 2020-09-04 |
| JP2021500362A (ja) | 2021-01-07 |
| EP3700529A1 (en) | 2020-09-02 |
| WO2019081235A1 (en) | 2019-05-02 |
| IL273169B1 (en) | 2024-01-01 |
| JP7196169B2 (ja) | 2022-12-26 |
| AU2018357775A1 (en) | 2020-03-19 |
| US20230405010A1 (en) | 2023-12-21 |
| US20190134043A1 (en) | 2019-05-09 |
| KR20200075864A (ko) | 2020-06-26 |
| CA3079299A1 (en) | 2019-05-02 |
| CN111278442A (zh) | 2020-06-12 |
| IL273169B2 (en) | 2024-05-01 |
| AU2024203045A1 (en) | 2024-05-23 |
| US20220378793A1 (en) | 2022-12-01 |
| MA50441A (fr) | 2020-09-02 |
| US11813266B2 (en) | 2023-11-14 |
| TW201929858A (zh) | 2019-08-01 |
| BR112020003973A2 (pt) | 2020-09-01 |
| TWI700088B (zh) | 2020-08-01 |
| IL309150A (en) | 2024-02-01 |
| PH12020550452A1 (en) | 2021-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000627A1 (es) | Nueva combinación de agentes activos para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas (pf-ild). | |
| AR125150A2 (es) | Sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma | |
| BR112014026643A2 (pt) | derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| DOP2016000175A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
| BR112016015838A8 (pt) | compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| BR112019011139A2 (pt) | conjugados que compreendem um agonista dual de glp/glucagon, um ligante e ácido hilaurônico | |
| BR112017026057A2 (pt) | profármacos constituídos por um conjugado linker de ácido hialurônico e agonista duplo de glp-1/glucagon | |
| PE20211789A1 (es) | Compuestos y su uso para el tratamiento de la deficiencia de 1-antitripsina | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| TR201908676T4 (tr) | Mesane idrar yolu hastalıklarının önlenmesinde veya tedavisinde kullanıma yönelik 2-asilaminotiyazol türevi. | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA202191286A1 (ru) | Ингибитор 15-pgdh | |
| BR112016029067A2 (pt) | ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios? | |
| CY1121345T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| BR112017006690A8 (pt) | Composto derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo | |
| UY33568A (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| BR112019008415A2 (pt) | composto de piridona e inibidor de c-met, composição farmacêutica e uso dos mesmos | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений |